Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases

Pharmacological Reviews

Volumn 67, Issue 2, 2015, Pages 280-309

  Siebert, Stefan ^a   Tsoukas, Alexander ^b   Robertson, Jamie ^a   McInnes, Iain ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ATACICEPT; AZATHIOPRINE; BRODALUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; IXEKIZUMAB; METHOTREXATE; NAPROXEN; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SARILUMAB; SECUKINUMAB; SILTUXIMAB; SIRUKUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CYTOKINE; IL6 PROTEIN, HUMAN; INTERLEUKIN 1; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ABNORMAL LABORATORY RESULT; ANAPHYLAXIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANKYLOSING SPONDYLITIS; ARTICLE; BACTERIAL PNEUMONIA; CANCER RISK; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; INFECTION; INFECTION RISK; INFLAMMATORY DISEASE; INJECTION SITE REACTION; INTESTINE PERFORATION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOENCEPHALOPATHY; MONOTHERAPY; NEOPLASM; NEUTROPENIA; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SPONDYLARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; UVEITIS; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MODEL; CROHN DISEASE; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SPONDYLITIS, ANKYLOSING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CROHN DISEASE; CYTOKINES; DRUGS, INVESTIGATIONAL; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PSORIASIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTORS;

EID: 84923331797     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.114.009639     Document Type: Article

References (313)

1. Agostini C (2001) Cytokine and chemokine blockade as immunointervention strategy for the treatment of diffuse lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 18: 18-22.
2. Aletaha D, Alasti F, and Smolen JS (2013) Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. Ann Rheum Dis 72:7-12.
3. Algood HM, Lin PL, and Flynn JL (2005) Tumor necrosis factor and chemokine interactions in the formation and maintenance ofgranulomas in tuberculosis. Clin Infect Dis 41 (Suppl 3):S189-S193.
4. Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, Preiss R, Arulmani U, Widmer A, Gitton X, et al. (2011) Efficacy and safety of the human anti-IL-1p monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 12:153.
5. Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, and Ranganathan P (2011) Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 50:1431-1439.
6. Anderson JJ, Baron G, van der Heijde D, Felson DT, and Dougados M (2001) An-kylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876-1886.
7. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, and Kavanaugh A; IMPACT 2 Trial Investigators (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150-1157.
8. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, et al. (2005b) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227-1236.
9. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. (2008) Two-year efficacy and safety ofinfliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35:869-876.
10. Armstrong N, Joore M, van Asselt T, Misso K, Manning N, Tomini F, Kleijnen J, and Riemsma R (2013) Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics 31:415-425.
11. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Coster L, Geborek P, et al. (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60:3180-3189.
12. Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, Ardizzone S, Pace F, and Sarzi-Puttini P (2013) Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 12:703-708.
13. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, and Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl JMed348:601-608.
14. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, et al. (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705-1713.
15. Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, and Sieper J (2013a) Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 15: R67.
16. Baraliakos X, Kiltz U, Heldmann F, Sieper J, and Braun J (2013b) Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. Clin Exp Rheumatol 31(4,78) 43-46.
17. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, et al. (2005) Clinical response to discontinuation ofanti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439-R444.
18. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sorensen H, et al. (2011a) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology (Oxford) 50:1690-1699.
19. Baraliakos X, Braun J, Laurent DD, Baeten D, Van Der Heijde D, Sieper J, and Emery P (2011b) Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging (Abstract). Arthritis Rheum 63 (10): 2486D.
20. Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, and Emery P (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60:946-954.
21. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, and Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305: 1460-1468.
22. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, and Wolbink GJ (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 69:817-821.
23. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, et al.; Sarcoidosis Investigators (2006) Inflix-imab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med174:795-802.
24. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, and Britton WJ (1999) Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 162: 3504-3511.
25. Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, Smith M, Thomas R, and Gaston H (2013) Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 15:R136.
26. Blum MA, Koo D, and Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33:901-913.
27. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, and Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285.
28. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sorensen H, et al. (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with anky-losing spondylitis over 5 years: evidence for different types ofresponse. Ann Rheum Dis 67:340-345.
29. Braun J, Baraliakos X, Listing J, and Sieper J (2005) Decreased incidence ofanterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52:2447-2451.
30. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, and Sieper J (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499-505.
31. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, et al. (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187-1193.
32. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, and Spencer-Green GT (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26-37.
33. Brennan FM, Chantry D, Jackson A, Maini R, and Feldmann M (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-247.
34. Brennan FM, Maini RN, and Feldmann M (1992) TNF alpha—a pivotal role in rheumatoid arthritis? Br J Rheumatol 31:293-298.
35. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41: 2196-2204.
36. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, et al.; for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) (2014) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2014:16 Epub ahead of print.
37. Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, and Emery P (2004) True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis 63:1344-1346.
38. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, and Rubbert-Roth A (2011) Effectiveness and safety ofthe interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IlIb real-life study (TAMARA). Ann Rheum Dis 70:755-759.
39. Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, et al. (2014) A randomised, double-blind, parallel-group study ofthe safety and efficacy ofsubcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying anti-rheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73:69-74.
40. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, et al.; EARTH Study Group Efficacy and safety ofmavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 72:1445-1452.
41. Bykerk VP, Ostor AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, Bensen W, Nurmohamed MT, Krause A, Bernasconi C, et al. (2012) Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 71:1950-1954.
42. Calich AL, Domiciano DS, and Fuller R (2010) Osteoarthritis: can anti-cytokine therapy play a role in treatment? Clin Rheumatol 29:451-455.
43. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, et al. (2002) Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475.
44. Chaparro M, Guerra I, Muňoz-Linares P, and Gisbert JP (2012) Systematic review: antibodies and anti-TNF-a levels in inflammatory bowel disease. Aliment Pharmacol Ther 35:971-986.
45. Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, and van Vollenhoven R; For the ARTIS group (2014) Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 2014:15 [Epub ahead ofprint].
46. Chatzidionysiou K and van Vollenhoven RF (2013) Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scand J Rheumatol 42:190-195.
47. Cheema GS, Roschke V, Hilbert DM, and Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313-1319.
48. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, and Burls A (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment ofrheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10: 3-4, 1-229.
49. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, and Appleton BE (2009) Intraarticular injection ofanakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 61:344-352.
50. Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, Roux C, Maugars Y, Mulleman D, Lukas C, et al.; On behalf of the French section of osteoarthritis Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 2014:19Epubaheadofprint.
51. Clark W, Jobanputra P, Barton P, and Burls A (2004) The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 8: 1105.
52. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, and McCabe D (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614-624.
53. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, et al.; 990145 Study Group (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63:1062-1068.
54. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, et al.; SONIC Study Group (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362:1383-1395.
55. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132:52-65.
56. Colombel JF, Sendid B, Jouault T, and Poulain D (2013) Secukinumab failure in Crohn's disease: the yeast connection? Gut 62:800-801.
57. Cook AD, Braine EL, Campbell IK, Rich MJ, and Hamilton JA (2001) Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase ofdisease. Arthritis Res 3:293-298.
58. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, et al. (2013) Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 9:e1003394.
59. Curtis JR, Lanas A, John A, Johnson DA, and Schulman KL (2012) Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:1819-1828.
60. Dávila-Fajardo CL, Márquez A, Pascual-Salcedo D, Moreno Ramos MJ, García-Portales R, Magro C, Alegre-Sancho JJ, Balsa A, Cabeza-Barrera J, Raya E, et al. (2014) Confirmation of-174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics 24:1-5.
61. Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, and Tsuji W; Enbrel Ankylosing Spondylitis Study Group (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48: 3230-3236.
62. Dayer JM, de Rochemonteix B, Burrus B, Demczuk S, and Dinarello CA (1986) Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 77:645-648.
63. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, et al.; PRINTO; PRCSG (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. NEnglJMed 367: 2385-2395.
64. De Benedetti F, Ruperto N, Brunner H, Grom AA, Wulffraat N, Henrickson M, Jerath R, Kimura Y, Kadva AK, Wang J, et al. (2014) A6: tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study. Arthritis Rheum (Munch) 66 11: 8-9.
65. Deleuran BW, Chu CQ, Field M, Brennan FM, Mitchell T, Feldmann M, and Maini RN (1992) Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions oftumor necrosis factor alpha. Arthritis Rheum 35:1170-1178.
66. Demin I, Hamrén B, Luttringer O, Pillai G, and Jung T (2012) Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. Clin Pharmacol Ther 92:352-359.
67. Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, et al. (2014) The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment ofSpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheum (Munch) 66:2649-2656.
68. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, and Rutgeerts P (1999) Endoscopic and his-tological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 116:1029-1034.
69. Dillon SR, Gross JA, Ansell SM, and Novak AJ (2006) An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5:235-246.
70. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, and Symmons DP; BSRBR Control Centre Consortium; BSR Biologics Register (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522-528.
71. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, and Symmons DP; British Society for Rheumatology Biologics Register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368-2376.
72. Doran MF, Crowson CS, Pond GR, O'Fallon WM, and Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287-2293.
73. Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Thabut G, Leblanc V, and Logeart I (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results ofa randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70:799-804.
74. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, et al. (2013) Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 72:43-50.
75. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, and Finckh A; Swiss Clinical Quality Management Physicians (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560-568.
76. Du Pan SM, Scherer A, Gabay C, and Finckh A (2012) Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 71:997-999.
77. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, et al. (1993) Treatment ofrheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36: 1681-1690.
78. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, and Sasso EH (2009) Less radiographic progression with adalimumab plus methotrexate versus meth-otrexate monotherapy across the spectrum ofclinical response in early rheumatoid arthritis. J Rheumatol 36:1429-1441.
79. Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Martinez Taboada VM, Barile-Fabris L, Moots RJ, Ostor A, Andrianakos A, et al. (2014) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 2014:29 Epub ahead of print.
80. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, and Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516-1523.
81. Fallahi-Sichani M, Flynn JL, Linderman JJ, and Kirschner DE (2012) Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol 188:3169-3178.
82. Fell HB and Jubb RW (1977) The effect of synovial tissue on the breakdown of articular cartilage in organ culture. Arthritis Rheum 20:1359-1371.
83. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, et al.; The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36:729-740.
84. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735.
85. Fénix-Caballero S, Alegre-del Rey EJ, Castaňo-Lara R, Puigventós-Latorre F, Borrero-Rubio JM, and López-Vallejo JF (2013) Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. JClinPharmTher38:286-293.
86. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, and Valesini G; GISEA Group (2008) Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 35:1944-1949.
87. Fiehn C, Wermann M, Pezzutto A, Hiifner M, and Heilig B (1992) [Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spon-dyloarthropathy]. Z Rheumatol 51:121-126.
88. Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg J, Jouanguy E, Boisson-Dupuis S, Fieschi C, Picard C, et al. (2006) Inborn errors of IL-12/23-and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 18:347-361.
89. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, and Gabay C; Arthritis (2010) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69:387-393.
90. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, and Sun G (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48:927-934.
91. Franklin JP, Symmons DP, and Silman AJ (2005) Risk of lymphoma in patients with RA treated with anti-TNFalpha agents. Ann Rheum Dis 64:657-658.
92. Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, Cortesi PA, and Turchetti G (2012) Systematic literature review on economic implications and pharmacoeconomic issues ofrheumatoid arthritis. Clin Exp Rheumatol 30(4,73) 72-84.
93. Furst DE (2004) Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment ofrheumatoid arthritis. Clin Ther 26:1960-1975.
94. Furst DE, Wallis R, Broder M, and Beenhouwer DO (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms ofaction may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36: 159-167.
95. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, etal.;ADACTAStudyInvestigators(2013a) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541-1550.
96. Gabay C and Kavanaugh A; ADACTA investigators (2013) Tocilizumab versus adalimumab for rheumatoid arthritis-Authors' reply. Lancet 382:395.
97. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, and Symmons DP; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register (2011a) Anti-TNF therapy is associated with an increased risk ofserious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50:124-131.
98. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, Watson KD, Lunt M, and Symmons DP; BSR Biologics Register (2011b) Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:1810-1814.
99. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, Watson KD, Lunt M, Hyrich KL, and Symmons DP (2013) Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 72:229-234.
100. Garcés S, Demengeot J, and Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72:1947-1955.
101. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, and Rolstad T (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53:573-577.
102. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecoc kE, Woodworth T, and Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968-2980.
103. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, and Bekker P; 20000223 Study Group (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412-1419.
104. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, etal. (2014a) One-yearefficacyandsafetyresults of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 41:414-421.
105. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, et al. (2013a) Efficacy and safety ofsecukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72:863-869.
106. Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, et al. (2014b) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheum (Munch) 66:1693-1704.
107. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, and Tak PP (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 63:1793-1803.
108. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, and Van Vollenhoven R (2013b) Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis ofupto4.6 years ofexposure. JRheumatol40:768-780.
109. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, and Sasso EH (2007) Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 56:476-488.
110. Glintborg B, 0stergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, et al. (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor a inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72:1149-1155.
111. Goh AX, Bertin-Maghit S, Ping Yeo S, Ho AW, Derks H, Mortellaro A, and Wang CI (2014) A novel human anti-interleukin-1p neutralizing monoclonal antibody showing in vivo efficacy. MAbs 6:765-773.
112. Gomez-Reino JJ and Carmona L; BIOBADASER Group (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29.
113. Gomez-Reino JJ, Maneiro JR, Ruiz J, Roselló R, Sanmarti R, and Romero AB; MIRAR Study Group (2012) Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis 71:1861-1864.
114. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, and Kavanaugh A (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633-640.
115. Graudal N and Jirgens G (2010) Similar effects ofdisease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 62:2852-2863.
116. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, and Hochberg MC; CORRONA Investigators (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69:380-386.
117. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, and Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307-311.
118. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, et al. (2011) Initiation of tumor necrosis factor-a antagonists and the risk ofhospitalization for infection in patients with autoimmune diseases. JAMA 306:2331-2339.
119. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo Xia Y, Zhou B, Li S, et al.; ACCEPT Study Group (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362: 118-128.
120. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999.
121. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, et al.; ACCENT I Study Group (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1549.
122. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Macintosh D, Panaccione R, Wolf D, and Pollack P (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CASSIC-I trial. Gas-troenterology 130:323-333, quiz 591.
123. Haroon M, Kirby B, and FitzGerald O (2013) High prevalence ofpsoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 72:736-740.
124. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, and Minden K; German Uveitis in Childhood Study Group (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification ofthe current screening guidelines. Rheumatology (Oxford) 46: 1015-1019.
125. Heldmann F, Brandt J, Vander Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, et al. (2011) The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with inflix-imab. Clin Exp Rheumatol 29:672-680.
126. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, et al.; All Departments of Rheumatology in Denmark (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22-32.
127. Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) (2014) Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 73:1114-1122.
128. Hostettler KE, Studler U, Tamm M, and Brutsche MH (2012) Long-term treatment with infliximab in patients with sarcoidosis. Respiration 83:218-224.
129. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, et al.; Psoriasis Study Group; Rheumatoid Arthritis Study Group; Uveitis Study Group (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2: 52-72.
130. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, et al.; Secukinumab in Crohn's Disease Study Group (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results ofa randomised, double-blind placebo-controlled trial. Gut 61:1693-1700.
131. Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, and Genovese MC (2014) Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 73:1626-1634.
132. Hyrich KL, Lunt M, Watson KD, Symmons DP, and Silman AJ; British Society for Rheumatology Biologics Register (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13-20.
133. Hyrich KL, Watson KD, Silman AJ, and Symmons DP; British Society for Rheumatology Biologics Register (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45:1558-1565.
134. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, et al.; Gruppo Italiano di Studio sulle Early Arthritides (GISEA) (2012) Longterm retention of tumor necrosis factor-a inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39:1179-1184.
135. Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, et al. (2012) Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idio-pathic arthritis. ModRheumatol 22:109-115.
136. Inman RD, Davis JC Jr, Heijde Dv, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, et al. (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58:3402-3412.
137. Inman RD and Maksymowych WP; CANDLE Study Group (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheu-matol 37:1203-1210.
138. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, vanSchaardenburg Stapel SO, Dijkmans BA, Aarden L, andWolbink GJ (2011) The presence orabsence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70:284-288.
139. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, et al. (2010) Comparison of tocilizumab monotherapyversus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88-96.
140. Jotanovic Z, Mihelic R, Sestan B, and Dembic Z (2012) Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review. Drugs Aging 29:343-358.
141. Juhász K, Buzás K, and Duda E (2013) Importance of reverse signaling of the TNF superfamily in immune regulation. Expert Rev Clin Immunol 9:335-348.
142. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, et al. (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976-986.
143. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, et al.; PSUMMIT-1 and 2 Study Groups (2014) Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radio-graphic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 73:1000-1006.
144. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, and Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med345:1098-1104.
145. Kekow J, Mueller-Ladner U, and Schulze-Koops H (2012) Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFa blocker failure. Biologics 6:191-199.
146. Keystone E, Heijde Dv, Mason D, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, et al. (2008) Certolizumab pegol plus metho-trexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58:3319-3329.
147. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, et al.; GO-FORWARD Study (2009) Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68:789-796.
148. Kirchner S, Holler E, Haffner S, Andreesen R, and Eissner G (2004) Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28:67-74.
149. Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise M, Dougados M, and Wajdula J; Etanercept Study 301 Investigators (2011) Assessment of long-term safety and efficacy ofetanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 29:238-247.
150. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al.; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675-681.
151. Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, Miki Y, Mimori T, Tomimoto H, and Takahashi R (2009) Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 48:1307-1309.
152. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, and Yamanaka H (2011) Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70:2148-2151.
153. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, and Fleischmann R (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of toci-lizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63:609-621.
154. Kristensen LE, Kapetanovic MC, Giilfe A, Soderlin M, Saxne T, and Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47:495-499.
155. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, and Lebwohl M; CNTO 1275 Psoriasis Study Group (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356: 580-592.
156. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, et al. (2013) A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 19: 3659-3670.
157. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, et al. (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spon-dylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73:39-47.
158. Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, and Fatenejad S (2006) Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 54: 3119-3125.
159. Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, and Kavanaugh A (2009) Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol 36: 1611-1617.
160. Leombruno JP, Einarson TR, and Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses ofserious adverse events. Ann Rheum Dis 68:1136-1145.
161. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, and Banerjee S (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med366:1190-1199.
162. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, and Gordon KB; PHOENIX 1 study investigators (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665-1674.
163. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, and Gottlieb AB; Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl JMed 349:2014-2022.
164. Lie E, van der Heijde D, Uhlig T, Mikkelsen K, R0devand E, Koldingsnes W, Kaufmann C, and Kvien TK (2011) Effectiveness of switching between TNF inhibitors in an-kylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 70: 157-163.
165. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, et al.; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. NEnglJMed 359: 810-820.
166. MacDonald TT, Hutchings P, Choy MY, Murch S, and Cooke A (1990) Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81:301-305.
167. Machado MA, Barbosa MM, Almeida AM, de Araújo VE, Kakehasi AM, Andrade EI, Cherchiglia ML, and Acurcio Fde A (2013) Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 33:2199-2213.
168. Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, and Genovese MC (2007) A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis ofthe hands. J Rheumatol 34:1323-1327.
169. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al.; ATTRACT Study Group (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932-1939.
170. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, et al.; CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817-2829.
171. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, et al. (2011) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment ofrheumatoid arthritis after the failure ofa tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 15:1-278.
172. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, and Emery P (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895-1904.
173. Mariette X, Reynolds AV, and Emery P (2012) Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors. Ann Rheum Dis 71:e2.
174. Martin DA, Churchill M, Flores-Suarez L, Cardiel MH, Wallace D, Martin R, Phillips K, Kaine JL, Dong H, Salinger D, et al. (2013) A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of broda-lumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 15:R164.
175. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, et al.; PSUMMIT 1 Study Group (2013) Efficacy and safety ofustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780-789.
176. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, et al. (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73:349-356.
177. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, et al. (2014a) Effect ofcertolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48-55.
178. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, and Nirula A (2014b) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370:2295-2306.
179. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, and Weinberg MA; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group (2005) Adalimumab for the treatment ofpatients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279-3289.
180. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, and Tsuji W (2004) Etanercept treatment ofpsoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264-2272.
181. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, and Gottlieb AB (2007) A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am AcadDermatol 56:e1-e15.
182. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, et al. (2008) Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 58: 106-115.
183. Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, Watson KD, Symmons DP, and Hyrich KL; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium (2013) Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 52:91-98.
184. Méric JC, Mulleman D, Ducourau E, Lauféron F, Miow Lin DC, Watier H, Goupille P, and Paintaud G (2011) Therapeutic drug monitoring of infliximab in spondyloar-thritis: an observational open-label study. Ther Drug Monit 33:411-416.
185. Mertens M and Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev (1):CD005121.
186. Miossec P and Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11:763-776.
187. Miserocchi E, Modorati G, Pontikaki I, Meroni PL, and Gerloni V (2014) Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 22:90-95.
188. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, and Harada M (2005) Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128:376-392.
189. Miyagi R, Ideguchi H, Soga T, Yamakawa Y, Otsuki H, Niino H, Shiina T, Ueda A, and Ishigatsubo Y (2014) Development of pulmonary and cardiac sarcoidosis during etanercept therapy. Int J Rheum Dis 17:810-812.
190. Morck B, Pullerits R, Geijer M, Bremell T, and Forsblad-d'Elia H (2013) Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. Mediators Inflamm 2013:289845.
191. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. AnnInternMed 130:478-486.
192. Murch SH, Braegger CP, Walker-Smith JA, and MacDonald TT (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705-1709.
193. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewé R, Smolen JS, Emery P, et al. (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheu-matic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976-986.
194. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, and Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73:516-528.
195. Navarro-Compán V, Moreira V, Ariza-Ariza R, Hernández-Cruz B, Vargas-Lebrón C, and Navarro-Sarabia F (2011) Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission ofthe disease. Clin Rheumatol 30:993-996.
196. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, and Villanueva I (2005) Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev (3): CD005113.
197. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, and Bourne T (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13:1323-1332.
198. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, and Kishimoto T (2007) Study of active controlled mono-therapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162-1167.
199. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, et al. (2014a) Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. ModRheumatol 24:17-25.
200. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, et al. (2014b) Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. ModRheumatol 24:26-32.
201. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, et al. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627-2632.
202. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, and Azuma J (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580-1584.
203. Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, et al.; Musashi Study Investigators (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:344-354.
204. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, and Lobb R (1989) Direct expression cloning ofvascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59:1203-1211.
205. O'Shea JJ, Laurence A, and McInnes IB (2013) Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 9:173-182.
206. Ostensen M and Forger F (2011) Treatment with biologics ofpregnant patients with rheumatic diseases. Curr Opin Rheumatol 23:293-298.
207. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, et al.; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators (2013a) Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years offollow-up. Br J Dermatol 168:844-854.
208. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, et al.; PHOENIX 2 study investigators (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675-1684.
209. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, and Richards HB (2013b) Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168:412-421.
210. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, et al. (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366:1181-1189.
211. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureňa S, Lim M, Lee YA, et al. (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72:1605-1612.
212. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, and Smolen JS (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cyto-kines in psoriatic arthritis synovial fluid. J Rheumatol 24:518-523.
213. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuňo L, Bonilla G, Nagore D, Ruiz Del Agua A, Martinez A, Aarden L, Martín-Mola E, et al. (2011) Influence of immu-nogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 50:1445-1452.
214. Perrier C, de Hertogh G, Cremer J, Vermeire S, Rutgeerts P, Van Assche G, Szymkowski DE,andCeuppensJL(2013)NeutralizationofmembraneTNF,butnotsolubleTNF,is crucial for the treatment ofexperimental colitis. Inflamm Bowel Dis 19:246-253.
215. Plasencia C, Pascual-Salcedo D, Nuňo L, Bonilla G, Villalba A, Peiteado D, Diez J, Nagore D, del Agua AR, Moral R, et al. (2012) Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 71:1955-1960.
216. Pober JS, Gimbrone MA Jr, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, and Springer TA (1986) Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 137:1893-1896.
217. Poddubnyy D, Hermann KG, Callhoff J, Listing J, and Sieper J (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73: 817-823.
218. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, et al. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors ofinterleukin-17 immunity. Science 332:65-68.
219. Raaschou P, Simard JF, Holmqvist M, and Askling J; ARTIS Study Group (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346:f1939.
220. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, and Landewé R (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73: 529-535.
221. Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, and Mease P (2012a) Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 167:180-190.
222. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, and Gordon KB; PHOENIX 1, PHOENIX 2, and ACCEPT investigators (2012b) An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 11:300-312.
223. Reichert JM (2013) Which are the antibodies to watch in 2013? MAbs 5:1.
224. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, et al. (2011) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60:780-787.
225. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, et al. (2013) Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168:402-411.
226. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, et al.; PSUMMIT 2 Study Group (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, mul-ticentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73:990-999.
227. Robertson J, Peters MJ, McInnes IB, and Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9: 513-523.
228. Rudwaleit M, R0devand E, Holck P, Vanhoof J, Kron M, Kary S, and Kupper H (2009a) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68:696-701.
229. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, et al. (2009b) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68: 777-783.
230. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476.
231. Saklatvala J (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547-549.
232. Saklatvala J, Sarsfield SJ, and Pilsworth LM (1983) Characterization of proteins from human synovium and mononuclear leucocytes that induce resorption of cartilage proteoglycan in vitro. Biochem J 209:337-344.
233. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, et al.; RATIO group (2011) Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70:616-623.
234. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, and Rutgeerts P; Ustekinumab Crohn's Disease Study Group (2008) A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135: 1130-1141.
235. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, et al.; PURSUIT-SC Study Group (2014) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85-95, quiz e14-e15.
236. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, et al.; PURSUIT-Maintenance Study Group (2014b) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:96-109,1.
237. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, and Schreiber S; PRECISE 1 Study Investigators (2007) Certolizumab pegol for the treatment ofCrohn's disease. NEngl JMed357:228-238.
238. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, et al.; CERTIFI Study Group (2012a) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367:1519-1528.
239. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, and Zinsmeister AR (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094.
240. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, and Thakkar RB (2012b) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastro-enterology 142:257-265,.
241. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350:876-885.
242. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, and Camez A; CHAMPION Study Investigators (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158:558-566.
243. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, and Grau R (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29:310-312.
244. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, and van Vollenhoven RF (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13:R141.
245. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, and Sandborn WJ; PRECISE 2 Study Investigators (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239-250.
246. Scirě CA, Caporali R, Sarzi-Puttini P, Frediani B, Di Franco M, Tincani A, Sinigaglia L, Sfriso P, Tirri R, Bellis E, et al.; Monitornet project (2013) Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and sero-negative spondyloarthritis: analysis from the MonitorNet database. Clin Exp Rheumatol 31:857-863.
247. Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y, Zhang L, Yuan ZR, Tan HS, et al. (2006) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 16:126-133.
248. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, and Trapnell BC (2001) GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15:557-567.
249. Shu T, Chen GH, Rong L, Feng F, Yang B, Chen R, and Wang J (2013) Indirect comparison of anti-TNF-a agents for active ankylosing spondylitis: mixed treatment comparison ofrandomized controlled trials. Clin Exp Rheumatol 31:717-722.
250. Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, et al.; All INFAST Investigators (2014a) Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73:101-107.
251. Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, et al.; All INFAST Investigators (2014b) Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 73:108-113.
252. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, and Pangan AL (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72:815-822.
253. Simard JF, Neovius M, and Askling J; ARTIS Study Group (2012) Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 64: 3502-3510.
254. Simonini G, Druce K, Cimaz R, Macfarlane GJ, and Jones GT (2014) Current evidence of anti-tumor necrosis factor a treatment efficacy in childhood chronic uve-itis: a systematic review and meta-analysis approach ofindividual drugs. Arthritis Care Res (Hoboken) 66:1073-1084.
255. Singh JA, Pando JA, Tomaszewski J, and Schumacher HR (2004) Quantitative analysis ofimmunohistologic features ofvery early rheumatoid synovitis in disease modifying antirheumatic drug-and corticosteroid-naive patients. JRheumatol 31:1281-1285.
256. Skoie IM, Wildhagen K, and Omdal R (2012) Development of sarcoidosis following etanercept treatment: a report ofthree cases. Rheumatol Int 32:1049-1053.
257. Smith MD, Triantafillou S, Parker A, Youssef PP, and Coleman M (1997) Synovial membrane inflammation and cytokine production in patients with early osteoar-thritis. J Rheumatol 24:365-371.
258. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, et al. (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68:797-804.
259. Smolen JS, Avila JC, and Aletaha D (2012) Tocilizumab inhibits progression ofjoint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: dis-association ofthe link between inflammation and destruction. Ann Rheum Dis 71: 687-693.
260. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, and Alten R; OPTION Investigators (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987-997.
261. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492-509.
262. Soderlin MK, Petersson IF, and Geborek P (2012) The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. ScandJ Rheumatol 41:1-9.
263. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, and Hyrich KL; British Society for Rheumatology Biologics Register (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:583-589.
264. Solomon DH, Mercer E, and Kavanaugh A (2012) Observationalstudiesontheriskof cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review oftheir methodologies and results. Arthritis Rheum 64:21-32.
265. Song IH, Haibel H, Poddubnyy D, Braun J, and Sieper J (2013a) Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol 31(4,78):37-42.
266. Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiss A, Freundlich B, Rudwaleit M, and Sieper J (2011) Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis 70:1257-1263.
267. Song IH, Wei B A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, Freundlich B, Rudwaleit M, et al. (2013) Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 72:823-825.
268. Spector TD (1990) Rheumatoid arthritis. Rheum Dis Clin North Am 16:513-537.
269. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nightingale P, Koutedakis Y, and Kitas GD (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 14:R160.
270. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, and Freundlich B (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340:c147.
271. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, and Zink A Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737-744.
272. Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, and Zink A (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5.
273. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, and Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 32:1597-1609.
274. Sullivan SD, Alfonso-Cristancho R, Carlson J, Mallya U, and Ringold S (2013) Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. J Med Econ 16:391-396.
275. Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK, Strek M, Caligiuri P, Machado RF, Niewold TB, et al. (2014) Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 31:46-54.
276. Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, et al. (2013) Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 65:2661-2671.
277. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, et al. (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single-and repeated-dose study. Arthritis Rheum 58:61-72.
278. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E, Saito K, Kaneko Y, Fukuyo S, et al. (2011) Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study. Rheumatology (Oxford) 50:1908-1915.
279. Tanaka E and Urata Y (2012) Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-a inhibitors. Hepatol Res 42:333-339.
280. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, and Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. NEngl JMed337:1029-1035.
281. Targan SR (2012) A Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe crohn's disease. Gastroenterology 142:S1.
282. Taylor PC (2010) Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 10:308-315.
283. Tenga G, Goěb V, Lequerré T, Bacquet-Deschryver H, Daragon A, Pouplin S, Lanfant-Weybel K, Le Loět X, Dieu B, and Vittecoq O (2011) A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Joint Bone Spine 78:50-55.
284. Ternant D, Mulleman D, Lauféron F, Vignault C, Ducourau E, Wendling D, Goupille P, and Paintaud G (2012) Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 73:55-65.
285. Tracey D, Klareskog L, Sasso EH, Salfeld JG, and Tak PP (2008) Tumor necrosis factor antagonist mechanisms ofaction: a comprehensive review. Pharmacol Ther 117:244-279.
286. Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen YK, and Leonardi C; PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups (2012) The safety ofustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 167:1145-1152.
287. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, et al.; Research Axed on Tolerance of Biotherapies Group (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884-1894.
288. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, et al. (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29-35.
289. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, and Schroeder DR (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177-185.
290. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, and Veys EM (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46:755-765.
291. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, and van Deventer SJ (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn'sdisease. Gastroenterology 124:1774-1785.
292. Van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, and Kupper H (2008) An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 27:1021-1028.
293. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, and Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582-591.
294. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, and Kupper H, et al.; ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136-2146.
295. Van der Linden S, Valkenburg HA, and Cats A (1984) Evaluation ofdiagnostic ccicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 63:1782-1792.
296. Van de Vosse E and Ottenhoff TH (2006) Human host genetic factors in mycriteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368.
297. Van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, Simpson D, Capra M, Liu T, Hsieh RK, et al. (2014) Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15:966-974.
298. Van Vollenhoven RF, Kinnman N, Vincent E, Wax S, and Bathon J (2011) Atao-bacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. Microbes Infect 8:1167-1173.
299. Verbruggen G, Wittoek R, Vander Cruyssen B, and Elewaut D (2012) Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the in-terphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 71:891-898.
300. Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, Koivuniemi R, Yli-Kerttula U, Mali M, and Sihvonen S, et al. (2011) Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 30: 1447-1454.
301. Vudattu NK, Holler E, Ewing P, Schulz U, Haffner S, Burger V, Kirchner S, Andreesen R, and Eissner G (2005) Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells. Immunology 115:536-543.
302. Wallis RS, Broder MS, Wong JY, Hanson ME, and Beenhouwer DO (2004) Granu-lomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261-1265.
303. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, and Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment ofrheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35-45.
304. Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, and Genovese MC (2013) Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results ofan open-label, clinical practice study. Arthritis Care Res (Hoboken) 65:362-371.
305. Williams RO, Feldmann M, and Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784-9788.
306. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, et al. (2013) Association between the initiation of anti-tumor necrosis factor therapy and the risk ofherpes zoster. JAMA 309:887-895.
307. Wolfe F and Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk ofmalignancy: analyses from a large US observational study. Arthritis Rheum 56:2886-2895.
308. Wozniak TM, Ryan AA, and Britton WJ (2006) Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. J Immunol 177: 8684-8692.
309. Xu WD, Firestein GS, Taetle R, Kaushansky K, and Zvaifler NJ (1989) Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 83:876-882.
310. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, et al. (2011) Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 21:122-133.
311. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, and Yao Y (2014) Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 141:125-139.
312. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, and Kavanaugh A (2012) Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 71:198-205.
313. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureňa S, et al. (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72:1613-1620.